IL17A and inflammatory bowel disease: Although the model may not directly reflect the pathological situations of clinical IBD nor IBS, and although IL-17A is not essential for induction of inflammation in this model, the present findings address the possibility that IL-17A may modulate GI motility in the healing stage after intestinal inflammation.